Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $652.00 at Robert W. Baird

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective cut by stock analysts at Robert W. Baird from $759.00 to $652.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the biopharmaceutical company's stock. Robert W. Baird's price objective would suggest a potential upside of 6.73% from the stock's current price.

Several other equities research analysts have also weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Piper Sandler decreased their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Truist Financial cut their target price on Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $945.32.

Regeneron Pharmaceuticals Trading Up 1.4 %

REGN traded up $8.22 during trading on Friday, reaching $610.86. 1,175,211 shares of the stock traded hands, compared to its average volume of 726,457. The stock has a market capitalization of $66.78 billion, a PE ratio of 15.96, a P/E/G ratio of 2.34 and a beta of 0.44. The stock's 50-day moving average is $637.38 and its 200 day moving average is $721.91. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business earned $11.86 EPS. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. Finally, Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.